SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Neurologi) ;pers:(Palmqvist Sebastian)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Neurologi) > Palmqvist Sebastian

  • Resultat 1-10 av 114
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Palmqvist, Sebastian, et al. (författare)
  • Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
  • 2015
  • Ingår i: Neurology. - : Lippincott Williams & Wilkins. - 1526-632X .- 0028-3878. ; 85:14, s. 1240-1249
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective:To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD).Methods:From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). -Amyloid (A) deposition in 9 brain regions was examined with [F-18]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study.Results:The best CSF measures for identifying MCI-AD were A42/total tau (t-tau) and A42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF A42/t-tau and A42/p-tau performed better than CSF A42 and A42/40 (AUC difference 0.03-0.12, p < 0.05). Using nonoptimized cutoffs, CSF A42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately.Conclusions:Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global A deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy.Classification of evidence:This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
  •  
2.
  • Borland, Emma, et al. (författare)
  • The Montreal Cognitive Assessment : Normative Data from a Large Swedish Population-Based Cohort
  • 2017
  • Ingår i: Journal of Alzheimer's Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 59:3, s. 893-901
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The Montreal Cognitive Assessment (MoCA) has a high sensitivity for detecting cognitive dysfunction. Swedish normative data does not exist and international norms are often derived from populations where cognitive impairment has not been screened for and not been thoroughly assessed to exclude subjects with dementia or mild cognitive impairment. Objective: To establish norms for MoCA and develop a regression-based norm calculator based on a large, well-examined cohort. Methods: MoCA was administered on 860 randomly selected elderly people from a population-based cohort from the EPIC study. Cognitive dysfunction was screened for and further assessed at a memory clinic. After excluding cognitively impaired participants, normative data was derived from 758 people, aged 65-85. Results: MoCA cut-offs (-1 to -2 standard deviations) for cognitive impairment ranged from <25 to <21 for the lowest educated and <26 to <24 for the highest educated, depending on age group. Significant predictors for MoCA score were age, sex and level of education. Conclusion: We present detailed normative MoCA data and cut-offs according to the DSM-5 criteria for cognitive impairment based on a large population-based cohort of elderly individuals, screened and thoroughly investigated to rule out cognitive impairment. Level of education, sex, and age should be taken in account when evaluating MoCA score, which is facilitated by our online regression-based calculator that provide percentile and z-score for a subject's MoCA score.
  •  
3.
  • Petrazzuoli, Ferdinando, et al. (författare)
  • Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline
  • 2020
  • Ingår i: Journal of Alzheimer's Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 75:4, s. 1191-1201
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Differentiating mild cognitive impairment (MCI) from subjective cognitive decline (SCD) is important because of the higher progression rate to dementia for MCI and when considering future disease-modifying drugs that will have treatment indications at the MCI stage. Objective: We examined if the two most widely-used cognitive tests, the Mini-Mental State Examination (MMSE) and clock-drawing test (CDT), and a test of attention/executive function (AQT) accurately can differentiate MCI from SCD. Methods: We included 466 consecutively recruited non-demented patients with cognitive complaints from the BioFINDER study who had been referred to memory clinics, predominantly from primary care. They were classified as MCI (n = 258) or SCD (n = 208) after thorough neuropsychological assessments. The accuracy of MMSE, CDT, and AQT for identifying MCI was examined both in training and validation samples and in the whole population. Results: As a single test, MMSE had the highest accuracy (sensitivity 73%, specificity 60%). The best combination of two tests was MMSE < 27 points or AQT > 91 seconds (sensitivity 56%, specificity 78%), but in logistic regression models, their AUC (0.76) was not significantly better than MMSE alone (AUC 0.75). CDT and AQT performed significantly worse (AUC 0.71; p < 0.001-0.05); otherwise no differences were seen between any combination of two or three tests. Conclusion: Neither single nor combinations of tests could differentiate MCI from SCD with adequately high accuracy. There is a great need to further develop, validate, and implement accurate screening-tests for primary care to improve accurate identification of MCI among individuals that seek medical care due to cognitive symptoms.
  •  
4.
  • Wuestefeld, Anika, et al. (författare)
  • Age-related and amyloid-beta-independent tau deposition and its downstream effects
  • 2023
  • Ingår i: Brain : a journal of neurology. - 1460-2156. ; 146:8, s. 3192-3205
  • Tidskriftsartikel (refereegranskat)abstract
    • Amyloid-β (Aβ) is hypothesized to facilitate the spread of tau pathology beyond the medial temporal lobe. However, there is evidence that, independently of Aβ, age-related tau pathology might be present outside of the medial temporal lobe. We therefore aimed to study age-related Aβ-independent tau deposition outside the medial temporal lobe in two large cohorts and to investigate potential downstream effects of this on cognition and structural measures. We included 545 cognitively unimpaired adults (40-92 years) from the BioFINDER-2 study (in vivo) and 639 (64-108 years) from the Rush Alzheimer's Disease Center cohorts (ex vivo). 18F-RO948- and 18F-flutemetamol-PET standardized uptake value ratios were calculated for regional tau and global/regional Aβ in vivo. Immunohistochemistry was used to estimate Aβ load and tangle density ex vivo. In vivo medial temporal lobe volumes (subiculum, cornu ammonis 1) and cortical thickness (entorhinal cortex, Brodmann area 35) were obtained using Automated Segmentation for Hippocampal Subfields packages. Thickness of early and late neocortical Alzheimer's disease regions was determined using FreeSurfer. Global cognition and episodic memory were estimated to quantify cognitive functioning. In vivo age-related tau deposition was observed in the medial temporal lobe and in frontal and parietal cortical regions, which was statistically significant when adjusting for Aβ. This was also observed in individuals with low Aβ load. Tau deposition was negatively associated with cortical volumes and thickness in temporal and parietal regions independently of Aβ. The associations between age and cortical volume or thickness were partially mediated via tau in regions with early Alzheimer's disease pathology, i.e. early tau and/or Aβ pathology (subiculum/Brodmann area 35/precuneus/posterior cingulate). Finally, the associations between age and cognition were partially mediated via tau in Brodmann area 35, even when including Aβ-PET as covariate. Results were validated in the ex vivo cohort showing age-related and Aβ-independent increases in tau aggregates in and outside the medial temporal lobe. Ex vivo age-cognition associations were mediated by medial and inferior temporal tau tangle density, while correcting for Aβ density. Taken together, our study provides support for primary age-related tauopathy even outside the medial temporal lobe in vivo and ex vivo, with downstream effects on structure and cognition. These results have implications for our understanding of the spreading of tau outside the medial temporal lobe, also in the context of Alzheimer's disease. Moreover, this study suggests the potential utility of tau-targeting treatments in primary age-related tauopathy, likely already in preclinical stages in individuals with low Aβ pathology.
  •  
5.
  • Mattsson, Niklas, et al. (författare)
  • 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
  • 2017
  • Ingår i: EMBO Molecular Medicine. - : EMBO. - 1757-4676 .- 1757-4684. ; 9, s. 1212-1223
  • Tidskriftsartikel (refereegranskat)abstract
    • To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand 18F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F-AV-1451, and mainly in demented AD patients. 18F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F-AV-1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18F-AV-1451 retention was always increased at this disease stage. We conclude that CSF T-tau and P-tau mainly behave as biomarkers of "disease state", since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18F-AV-1451 is a biomarker of "disease stage", since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.
  •  
6.
  •  
7.
  • Palmqvist, Sebastian, et al. (författare)
  • Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
  • 2012
  • Ingår i: Plos One. - : Public Library of Science (PLoS). - 1932-6203. ; 7:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Early identification of Alzheimer's disease (AD) is needed both for clinical trials and in clinical practice. In this study, we compared brief cognitive tests and cerebrospinal fluid (CSF) biomarkers in predicting conversion from mild cognitive impairment (MCI) to AD. Methods: At a memory clinic, 133 patients with MCI were followed until development of dementia or until they had been stable over a mean period of 5.9 years (range 3.2-8.8 years). The Mini-Mental State Examination (MMSE), the clock drawing test, total tau, tau phosphorylated at Thr(181) (P-tau) and amyloid-beta(1-42) (A beta(42)) were assessed at baseline. Results: During clinical follow-up, 47% remained cognitively stable and 53% developed dementia, with an incidence of 13.8%/year. In the group that developed dementia the prevalence of AD was 73.2%, vascular dementia 14.1%, dementia with Lewy bodies (DLB) 5.6%, progressive supranuclear palsy (PSP) 4.2%, semantic dementia 1.4% and dementia due to brain tumour 1.4%. When predicting subsequent development of AD among patients with MCI, the cognitive tests classified 81% of the cases correctly (AUC, 0.85; 95% CI, 0.77-0.90) and CSF biomarkers 83% (AUC, 0.89; 95% CI, 0.82-0.94). The combination of cognitive tests and CSF (AUC, 0.93; 95% CI 0.87 to 0.96) was significantly better than the cognitive tests (p = 0.01) and the CSF biomarkers (p = 0.04) alone when predicting AD. Conclusions: The MMSE and the clock drawing test were as accurate as CSF biomarkers in predicting future development of AD in patients with MCI. Combining both instruments provided significantly greater accuracy than cognitive tests or CSF biomarkers alone in predicting AD.
  •  
8.
  • Palmqvist, Sebastian, et al. (författare)
  • The usefulness of cube copying for evaluating treatment of Alzheimer's disease.
  • 2008
  • Ingår i: American Journal of Alzheimers Disease & other Dementias. - : SAGE Publications. - 1938-2731 .- 1533-3175. ; 23:5, s. 439-446
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims: Cube copying measures visuospatial ability, which is often impaired in Alzheimer's disease (AD). Cube copying was examined as an evaluation of cholinesterase inhibitor (ChEI) treatment in AD. Methods: Eighty-five ChEI-treated AD patients were included. Cube drawings made at prebaseline, baseline, 6 months, and 12 months were assessed. Cube drawings from 56 healthy individuals were also examined. Results: The healthy individuals remained stable in cube copying, whereas untreated AD patients deteriorated during a median period of 6 months. When treatment was given, the deterioration was interrupted. After 12 months, Mini-Mental State Examination (MMSE) had deteriorated compared with baseline whereas cube copying was unchanged.Conclusions: The results indicate that cube copying can be used to evaluate ChEI treatment. It might also show a more long-lasting response to treatment than MMSE. Cube copying only measures a narrow cognitive function and can preferably be used with MMSE, which evaluates visuospatial ability poorly.
  •  
9.
  • Palmqvist, Sebastian (författare)
  • Validation of brief cognitive tests in mild cognitive impairment, Alzheimer's disease and dementia with Lewy bodies.
  • 2011
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Background It is estimated that 34 million people suffer from dementia, costing society US$422 billion each year. Alzheimer’s disease (AD) is the most common dementia and the global prevalence is predicted to increase to over 100 million people by the year 2050, with the greatest increase in developing countries. Therefore, inexpensive and efficient instruments are required for investigation and evaluation. Aim To evaluate the brief cognitive tests cube copying, clock drawing, the Mini-Mental State Examination (MMSE) and A Quick Test of Cognitive Speed (AQT) in the early diagnosis, treatment evaluation and differential diagnosis of dementias. Populations I. 85 patients with AD. II. 33 patients with dementia with Lewy bodies (DLB) and 66 with AD. III. 75 patients with AD. IV. 99 patients with mild cognitive impairment (MCI). Findings I. Cube copying was found useful for evaluating treatment with acetylcholinesterase inhibitors (AChEI) in patients with AD. II. Easy and quick interpretations of the MMSE, clock drawing and cube copying differentiated patients with DLB from patients with AD. III. AQT was twice as sensitive as the MMSE in detecting treatment response to AChEI in patients with AD. IV. The MMSE, AQT and clock drawing were as accurate as cerebrospinal fluid biomarkers (tau, Aβ42 and P-tau) in predicting development of AD and dementia in mild cognitive impairment during an average of five years. Conclusion This thesis has improved the validity of brief cognitive tests and contributed with results that can be clinically relevant for evaluating treatment of AD, differentiating DLB from AD, and predicting development of AD and other dementias.
  •  
10.
  • Cullen, Nicholas C., et al. (författare)
  • Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
  • 2021
  • Ingår i: Nature Aging. - : Springer Science and Business Media LLC. - 2662-8465. ; 1, s. 114-123
  • Tidskriftsartikel (refereegranskat)abstract
    • We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included in the study. The primary outcomes were longitudinal cognition and conversion to Alzheimer’s disease (AD) dementia. A model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL), but not Aβ42/Aβ40, had the best prognosis performance of all models (area under the curve = 0.88 for 4-year conversion to AD in BioFINDER, validated in ADNI), was stronger than a basic model of age, sex, education and baseline cognition, and performed similarly to cerebrospinal fluid biomarkers. A publicly available online tool for individualized prognosis in MCI based on our combined plasma biomarker models is introduced. Combination of plasma biomarkers may be of high value to identify individuals with MCI who will progress to AD dementia in clinical trials and in clinical practice.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 114
Typ av publikation
tidskriftsartikel (112)
konferensbidrag (1)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (111)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Hansson, Oskar (101)
Stomrud, Erik (69)
Janelidze, Shorena (43)
Mattsson-Carlgren, N ... (41)
Smith, Ruben (30)
visa fler...
Strandberg, Olof (29)
Ossenkoppele, Rik (24)
van Westen, Danielle (21)
Blennow, Kaj, 1958 (20)
Zetterberg, Henrik, ... (18)
Leuzy, Antoine (18)
Mattsson, Niklas (18)
Minthon, Lennart (11)
Blennow, Kaj (9)
Jögi, Jonas (9)
Zetterberg, Henrik (9)
Londos, Elisabet (8)
Pereira, Joana B (8)
Ohlsson, Tomas (8)
Cullen, Nicholas C (7)
Binette, Alexa Piche ... (6)
Dage, Jeffrey L. (5)
Ashton, Nicholas J. (5)
Rabinovici, Gil D (5)
La Joie, Renaud (5)
Klein, Gregory (5)
Nägga, Katarina (5)
Westman, Eric (4)
Berron, David (4)
Schöll, Michael (4)
Nilsson, Maria H. (4)
Schöll, Michael, 198 ... (4)
Dage, J. L. (4)
Hall, Sara (4)
Wattmo, Carina (4)
Wahlund, Lars-Olof (3)
Nilsson, Markus (3)
van der Flier, Wiesj ... (3)
Teunissen, Charlotte ... (3)
Barkhof, Frederik (3)
Salvadó, Gemma (3)
Thulesius, Hans (3)
Hardy, John (3)
Groot, Colin (3)
Mattsson, Niklas, 19 ... (3)
Petrazzuoli, Ferdina ... (3)
Santillo, Alexander (3)
Bateman, Randall J (3)
Vogel, Jacob W. (3)
visa färre...
Lärosäte
Lunds universitet (111)
Göteborgs universitet (27)
Karolinska Institutet (15)
Linköpings universitet (4)
Linnéuniversitetet (3)
Örebro universitet (2)
visa fler...
Uppsala universitet (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (112)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (114)
Naturvetenskap (2)
Samhällsvetenskap (2)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy